Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.

For more details, visit Merus’ website and social media channels.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET.

The webcast of the panel discussion will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

FAQ

When is Merus N.V.'s participation in the Citi BioPharma Conference?

Merus N.V. will participate in the Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET.

Where can I watch the Merus N.V. panel discussion?

The panel discussion can be watched live on the Investors page of Merus N.V.'s website.

What type of products is Merus N.V. developing?

Merus N.V. is developing innovative multispecific antibodies known as Biclonics® and Triclonics®.

Who will represent Merus N.V. at the conference?

Bill Lundberg, M.D., will represent Merus N.V. as the President and CEO at the conference.

Is there an archive of the Merus N.V. conference presentation?

Yes, an archived presentation of the Merus N.V. panel discussion will be available for a limited time after the event.